Skip to main content
. 2023 Jul 7;13:1218552. doi: 10.3389/fcimb.2023.1218552

Table 2.

Demographic information and clinical data of patients in both the probiotic and nonprobiotic groups.

Probiotic group Nonprobiotic group
  Gender
Male 37 40
Female 7 18
Age 55.00 ± 12.74 51.52 ± 13.50
  Pathogenesis
Hepatitis 17 26
Alcoholic 10 9
Mixed Pathogenesis 8 8
unclassified 9 15
  Child-pugh grade
A 4 16
B 25 28
C 15 14
Pretreatment Post-treatment Pretreatment Post-treatment
WBC 3.52(2.71-4.52) 3.57(2.49-4.60) 3.50(2.47-4.59) 3.35(2.48-4.35)
N% 63.03 ± 11.74 60.39 ± 11.19* 63.21 ± 13.21 57.29 ± 12.93*
Hb 110.8 ± 21.28 109.77 ± 21.86 103.81 ± 24.98 102.21 ± 24.22
PLT 66.50(41.00-99.75) 68(43.25-105.00) 64.00(45.75-108.00) 67.50(45.75-103.25)
ALT 31.85(26.55-45.95) 23.35(18.10-36.83)*+ 39.90(25.58-55.98) 33.70(21.75-53.78)*
AST 52.00(33.83-76.55) 41.10(25.65-53.53)* 57.85(41.20-77.45) 46.35(36.18-66.28)*
TBIL 39.90(28.80-59.00) 27.80(17.75-46.78)*+ 37.60(29.68-56.88) 34.90(26.08-49.13)*
TBA 49.40(23.98-94.75) 45.50(19.00-77.50)* 51.65(23.08-106.05) 44.60(24.83-76.83)*

*indicates a statistically significant difference between pre- and posttreatment (p < 0.05). +indicates a statistically significant difference between the probiotic and nonprobiotic groups posttreatment (p < 0.05).